Format

Send to

Choose Destination
See comment in PubMed Commons below
Ophthalmology. 2013 May;120(5 Suppl):S23-5. doi: 10.1016/j.ophtha.2013.01.059.

Neovascular age-related macular degeneration: individualizing therapy in the era of anti-angiogenic treatments.

Abstract

The treatment of neovascular age-related macular degeneration (AMD) had been revolutionized by the use of anti-vascular endothelial growth factor (VEGF) drugs: bevacizumab and ranibizumab. With the introduction of a third anti-VEGF drug, aflibercept, ophthalmologists have several options to choose from, as well as various treatment regimens they can follow. In this Interview, Jeffrey S. Heier, MD, of Ophthalmic Consultants of Boston, Massachusetts, discusses his approaches to managing the treatment of patients with AMD and providing them with individualized care.

PMID:
23642783
DOI:
10.1016/j.ophtha.2013.01.059
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center